Subscription Shift: Hims & Hers Faces Investor Scrutiny Over New Pricing Strategy

The telehealth company Hims & Hers has initiated the long-anticipated distribution of official Novo Nordisk weight-loss medications. On Wall Street, however, this milestone has generated more concern than celebration. Market observers are focused on a new pricing structure that may erode the firm's established competitive edge as a lower-cost provider.

A Strategic Pivot with Financial Implications

Beginning March 26, the platform started offering approved GLP-1 drugs, including Wegovy and Ozempic. This move concludes a period of significant regulatory risk. The company had previously removed cheaper, compounded versions of these drugs from its offerings following a lawsuit from Novo Nordisk, warnings from the U.S. FDA, and the threat of a Department of Justice investigation.

While securing legal safety, this agreement fundamentally alters the company's market positioning. Hims & Hers is no longer actively promoting these compounded products and will only supply them in exceptional cases where they are medically necessary.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Market Experts Flag Subscription Model Concerns

This strategic realignment is precisely what is worrying investors. For a subscription to the branded medications, the company now charges $149 per month—a figure that does not yet include the actual cost of the drugs. Analysts at Bank of America view this price as slightly above expectations, noting that competitors like Ro are operating at a lower price point of $145.

Experts fear the transition from a budget-friendly option to a mid-priced service could stifle growth. Bank of America projects that the GLP-1-related business could decline by 31% in 2026, suggesting even this estimate may be optimistic. Reflecting similar caution, TD Cowen reduced its price target on the stock from $25 to $23 last Friday.

Share Price Under Pressure

These skeptical assessments are reflected in recent trading activity. After climbing to around $27 in early March following news of the Novo Nordisk deal, the shares have since settled near the $19 mark. A substantial short interest of approximately 83.3 million shares, equating to about 40% of the freely tradable float, underscores the persistent doubt among market participants.

Despite the current headwinds, the company reported a strong fiscal 2025, with revenue jumping to $2.35 billion. Management is targeting revenue between $2.7 billion and $2.9 billion for 2026. Concrete data on how the new pricing strategy affects subscriber numbers and margins will be revealed in the next quarterly report, scheduled for May 11, 2026.

Ad

Hims & Hers Stock: New Analysis - 30 March

Fresh Hims & Hers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Hims & Hers analysis...

US4330001060 | SHIFT | boerse | 69027341 |